Evaluating Impurities in Drugs (Part II of III)

March 1, 2012
Ponnaiah Ravi

,
Kashyap R. Wadekar

,
S. Srinivasa Rao

,
E. Balasubrahmanyam

,
Mitali Bhalme

,
L. Sampath Kumar

,
K. Vigneshwar Reddy

Pharmaceutical Technology Europe

Pharmaceutical Technology Europe, Pharmaceutical Technology Europe-03-01-2012, Volume 24, Issue 3

In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.

By Kashyap R. Wadekar, Mitali Bhalme, S. Srinivasa Rao, K. Vigneshwar Reddy, L. Sampath Kumar, E. Balasubrahmanyam

The public and the pharmaceutical industry are placing greater attention on impurities in drug as evidenced by the attention given to pharmaceutical impurities in books, journal articles, and national and international guidelines. The health implications of impurities can be significant because of their potential teratogenic, mutagenic, or carcinogenic effects. Controlling and monitoring impurities in APIs and finished drug products, therefore, is a crucial issue in drug development and manufacturing.

This article was also published in our US sister publication Pharmaceutical Technology and can be read here.